Tata India Pharma & Healthcare Fund Regular Growth
NAV ₹33.5429 on 13 November 2026
AMFI name: Tata India Pharma & Healthcare Fund-Regular Plan-Growth · Scheme code 135812 · ISIN INF277K016A9
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY HEALTHCARE INDEX TRI | Category median |
|---|---|---|---|
| 1M | +7.22% | +8.67% | +5.63% |
| 6M | +5.89% | +12.84% | +6.99% |
| 1Y | +8.89% | +38.92% | +2.83% |
| 3Y | +17.27% | +28.05% | +13.18% |
| 5Y | +14.09% | - | +10.85% |
Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare TRI, which we do not hold, so this is the closest NSE index.
Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Scheme - Sectoral/ Thematic” category, up to 174 funds with clean data. Ranks are under “Rank among peers”.
Risk
From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.
- Volatility
- 13.37%
- Annualised, 3 years
- Max drawdown
- -16.99%
- Worst fall from a peak, 3 years
- Sharpe ratio
- 0.84
- Return above the risk-free rate per unit of volatility, 3 years
- Sortino ratio
- 1.21
- Like Sharpe, counting only falls, 3 years
- Alpha
- +0.17%
- Return a year beyond what beta explains, 3 years
- Beta
- 0.53
- 1.00 moves in step with the benchmark, 3 years
- Upside capture
- 47%
- Share of the benchmark's rises captured, 3 years
- Downside capture
- 94%
- Share of the benchmark's falls taken (lower is better), 3 years
Every 3-year holding period
Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.
Rank among peers
Regular plans, Growth option, in AMFI's “Equity Scheme - Sectoral/ Thematic” category. Each rank counts only the peers that have that figure.
| Rank | Scheme Name | 3Y Return | 1Y Return | Sharpe | Direct TER | AUM |
|---|---|---|---|---|---|---|
| #1 | Nippon India Mutual Fund | +46.52% | +60.64% | 1.07 | 1.06% | ₹1,100 Cr |
| #2 | HDFC Mutual Fund | +33.64% | +20.34% | 1.07 | 0.89% | ₹11,128 Cr |
| #3 | HDFC Mutual Fund | +31.28% | +31.60% | 1.76 | 1.03% | ₹3,128 Cr |
| #4 | SBI Mutual Fund | +25.42% | +26.07% | 1.47 | 0.76% | ₹5,565 Cr |
| #5 | HDFC Mutual Fund | +24.77% | +10.10% | 1.09 | 1.10% | ₹1,997 Cr |
| #6 | Mirae Asset Mutual Fund | +24.42% | +27.89% | 1.28 | - | ₹3,458 Cr |
| #7 | UTI Mutual Fund | +23.89% | +22.00% | 1.31 | 1.35% | ₹1,399 Cr |
| #8 | ICICI Prudential Mutual Fund | +22.73% | +10.29% | 0.95 | 2.08% | ₹3,926 Cr |
| #39 | Tata India Pharma & Healthcare FundCurrent Fund Tata Mutual Fund | +17.27% | +8.89% | 0.84 | 1.07% | ₹1,534 Cr |
Costs and fund facts
- Expense ratio (stated maximum)
- Direct 1.07% · Regular 2.37%
- Exit load
- 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.
- Fund size (all plans)
- ₹1,534 CrAverage, quarter to September 2026
- Benchmark
- BSE Healthcare TRICompared here with NIFTY HEALTHCARE INDEX TRI
- Allotment date
- 28 December 2015Scheme document
- Type
- An open ended equity scheme investing in Pharma and Healthcare Services Sector.
- AMFI scheme code
- 135812
Fund manager
- Rajat Srivastavasince 16-Sep-2024
How each manager has done since taking over: fund manager scorecard.
Investment objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
About this fund
Tata India Pharma & Healthcare Fund Regular Growth is a mutual fund scheme from Tata Mutual Fund, listed by AMFI under “Equity Scheme - Sectoral/ Thematic”. This page covers the Regular plan with the Growth option. Its NAV was ₹33.5429 on 13 November 2026. It returned 8.89% over 1 year, 17.27% a year over 3 years and 14.09% a year over 5 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. Its 3-year return ranks #39 of 142 Regular Growth plans in the same AMFI category. Q-Score: 68 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹1,534 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 2.37% a year for the Regular plan. Managed by Rajat Srivastava. Its scheme summary document gives the allotment date as 28 December 2015.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.
Plans and options of this fund (1)
| Plan | Option | ISIN | AMFI code | NAV |
|---|---|---|---|---|
| Direct | Growth | INF277K019A3 | 135810 | ₹39.7613 Nov 2026 |